AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.